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Exogenous nitric oxide prevents endotoxin-induced glomerular
thrombosis in rats
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Department of Medicine, Veterans Administration Medical Center, and the University of Minnesota School of Medicine, Minneapolis, Minnesota, USA
Exogenous nitric oxide prevents endotoxin-induced glomerular throm-
bosis in rats. Nitric oxide (NO) synthesized from L-arginine is an
endogenous vasodilator and inhibitor of platelet adhesion and aggrega-
tion. Gram-negative lipopolysaccharide (LPS) can induce NO synthesis,
which may mediate the pathophysiologic effects of endotoxemia. In
addition, our previous studies suggested that LPS-induced NO may
protect against thrombosis in rats. In the present study, male Sprague-
Dawley rats given LPS (0.1 mg/kg) i.p. increased their urinary excretion of
NO2 + NO3 (stable end-products of NO) by 4.3-fold. Rats given 10
rg/kg/hr i.v. of nitroglycerin (GTN), an exogenous NO donor, showed a
similar increase. L-NAME, an inhibitor of NO synthesis, abrogated the
increase in urinary NO2 + NO3 in LPS-treated rats but not in rats given
GTN. Glomerular thrombosis developed in rats given LPS + L-NAME
(thrombosis score = 3.02 0.4), while those given LPS + L-NAME +
GTN were largely protected (thrombosis score = 1.37 0.5, P < 0.05).
Atrial natriuretic peptide (ANP), an NO-independent vasodilator, neither
increased urinary NO2 + NO3 nor prevented glomerular thrombosis(thrombosis score = 2.68 0.5, NS). Hydralazine, another vasodilator
without effects on NO or platelets, also failed to prevent glomerular
thrombosis in rats given LPS + L-NAME. We conclude that in endotox-
emia, the antithrombogenic properties of endogenously synthesized NO
are important in preventing alomerular thrombosis. The exogenously NO
donor, GTN, can substitute for the antithrombogenic effect of endogenous
NO. Clinically, administration of NO synthesis inhibitors to treat endo-
toxic shock may need to be combined with concomitant administration of
exogenous NO donors to prevent microvascular thrombosis.
Endotoxin, a lipopolysacharide (LPS) from gram negative
bacteria (LPS), and certain cytokines, have been demonstrated to
induce endothelial injuly and intravascular coagulation, often
leading to glomerular thrombosis [1—3]. LPS and/or cytokines,
released during endotoxemia, increase expression of the inducible
nitric oxide synthase (NOS) [4, 5], leading to synthesis of large
amounts of nitric oxide (NO) from its precursor L-arginine. NO
induces vascular relaxation and inhibits platelet aggregation via
increased synthesis of cGMP due to activation of soluble guany-
late cyclase [6]. Thus, NO may play an important role in the
hypotension observed during endotoxemia or sepsis [3]. On the
other hand, in the kidney increased NO formation may be
important in maintaining renal perfusion during shock and pre-
venting platelet aggregation and thrombosis in glomeruli [7]. We
have previously shown that rats given LPS have a marked increase
in the urinary excretion rate of NO2 + NO3, the stable end
products of NO, and do not develop glomerular thrombosis.
However, if LPS-induced synthesis of NO is prevented by prior or
concomitant treatment with an L-arginine analog, such as NG
nitro-L-arginine methyl ester ( L-NAME), generalized glomerular
thrombosis occurs [7].
In human septic shock, severe vasodilation, hypotension, vas-
cular damage and disseminated intravascular coagulation can be
observed. The persistent hypotension and low systemic vascular
resistance are usually resistant to vasoconstrictors such as norepi-
nephrine. Even in critical care units, the mortality rate of these
patients remains high [8]. Recent reports have demonstrated that
inhibition of NOS will quickly restore blood pressure to normal in
both animals and humans with endotoxemia [9—11]. However, in
rats and in dogs with endotoxemia the administration of an NOS
inhibitor resulted in increased mortality [7, 12]. In a recent study,
Wright, Rees and Moncada [13] reported that in rabbits that
received LPS, blocking of NOS with an arginine analog, results in
irreversible shock and increased mortality. The administration of
an NO donor, S-nitroso-N-acetyl-penicillamine, improved perfu-
sion, prevented shock and led to a decreased mortality. Unfortu-
nately, intravascular coagulation or thrombosis was not investi-
gated in that study.
If NOS inhibitors are to be useful in septic shock, adverse
effects such as glomerular thrombosis will have to be prevented.
We therefore undertook the present study to explore whether
intravenous administration of an exogenous NO donor, nitroglyc-
erin (glyceryl trinitrate, GTN), could substitute for endogenous
NO and prevent glomerular thrombosis induced by LPS in
L-NAME-treated rats, To evaluate whether the vasodilation
induced by NO was important in the prevention of glomerular
thrombosis, we compared the effect of GTN with that of two other
vasodilators, atrial natriuretic peptide (ANP) and hydralazine.
ANP has been shown to be effective in preventing acute renal
failure after ischemia [14, 15], and is known to increase cGMP via
particulate guanylate cyclase. Hydralazine, on the other hand,
causes direct vascular smooth muscle relaxation, probably via
effects on calcium.
Methods
Experimental design
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The experimental design used in these studies is described in
Figure 1. Male Sprague-Dawley rats (275 to 350 g, Harlan
Laboratories, Indianapolis, Illinois, USA) were used in all studies.
Rats were fasted for six hours and then placed in metabolic cages
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Anesthesia Intravenous infusion, GTN,ANP or saline=
Sacrifice
L-NAME4 1 1
6 hr 16-hr baseline —1 0 1 2 3 4 5 6 7
fasting urine
collection Urine collection, hours
for overnight (16 hr) urine collections to determine baseline
urinary NO2 + NO3 excretion. Water was provided ad libitum,
and rats were fasted for the duration of the experiment. The rats
were then briefly anesthetized (Brevital 100 mg/kg i.p.) and a
PE-50 catheter was placed in the femoral vein, tunneled subcuta-
neously and extruded in the posterior cervical region for the
constant infusion of GTN, ANP, hydralazine or saline vehicle. No
heparin was administered. A baseline blood sample was obtained
from the femoral vein. Once awake, the rats were kept in
individual metabolic cages for the seven hours of the experiment
(Fig. 1). The following five experimental groups were studied:
Group 1. LPS + L-N4JvIE (N = 19). These rats were given LPS
(0.1 mg/kg i.p.) at time 0 and L-NAME (75 mg/kg i.p.) at —30
minutes and 0, 2, 4 and 6 hours after the LPS injection. In five of
these rats, a catheter was introduced in the femoral vein as
described above. These rats received normal saline intravenously
(1.2 ml/hr) beginning one hour before the LPS injection. These
rats were used as controls to evaluate the effects of volume
substitution and instrumentation as given in rats in the other
groups.
Group 2. LPS + L-NAME + GTN (N = 15). L-NAME and LPS
were given as in Group 1. In addition, GTN was dissolved in
sterile saline in a glass vial, aspirated into a glass syringe and
infused via the femoral vein catheter at a rate of 1.2 mI/hr. GTN
infusion was started at —60 minutes, at 2 g/kg/min and increased
stepwise to 10 jxg/kg/min over the next hour. This dose was
continued for the rest of the experiment.
Group 3, LPS + L-NAME + ANP (N = 12). LPS and L-NAME
were given as in Group 1. In addition, ANP, dissolved in normal
saline, was infused at a rate of 1.2 ml/hr, beginning at —60 minutes
at 2 jxg/kg/hr with a stepwise increase to a maximum of 16
pg/kg/hr [14], and kept at this rate for the duration of the
experiment.
Group 4. GTN only (N 4). LPS and L-NAME were not given
in this group. These rats were given only an infusion of GTN in
normal saline in a concentration and at a rate identical to that
given in Group 2.
Group 5. LPS only (N 15). These rats were injected i.p at time
0 with LPS (0.1 mg/kg). No other injections or infusions were
given.
An additional group of rats (N = 7) was given LPS + L-NAME
and an intravenous infusion of a different vasodilator, hydralazine.
The protocol for these experiments was exactly as for the groups
given LPS + L-NAME + GTN or ANP. Based on previous
studies [16], we gave hydrazaline at a dose of 0.4 mg/kg/hr in a
volume of 1.2 ml/hr, which resulted in blood pressures comparable
to that in the LPS + L-NAME + GTN group.
To measure intrarterial blood pressure, subgroups of rats in
each group (Group 1, 5 rats; Group 2, 4 rats; Group 3, 5 rats,
Group 5, 3 rats), a PE-50 catheter was placed in the femoral artery
for continuous blood pressure monitoring (TNF transducer,
Gould, Oxnard, California, USA). As small doses of heparin were
required to maintain line patency in these rats, kidney tissue from
these rats was not used for the morphologic studies.
Seven hours (8 hr for group 5) after the injection of LPS, rats
were anesthetized with mactin (5-butyl-5-ethyl-thiobarbituric
acid, 100 mg/kg i.p.). The left kidney was removed through a
midline incision and processed for morphologic analysis. A final
blood sample was collected from the aorta and the animals killed
by exsanguination.
Moi'phologic analysis
Kidney tissue was fixed in buffered formalin and stained with
the Periodic acid Schiff (PAS) technique. The stained sections
were coded and read without knowledge of which group the tissue
came from. The extent of the deposition of fibrin-like PAS
positive material in the capillaries was evaluated. We have
previously shown by immunofluorescence microscopy that these
deposits do in fact contain fibrin [7]. The percentage of capillaries
in each glomeruli which contained fibrin thrombosis was the basis
for a semi-quantitative score: Score 0: No thrombosis seen; Score
1: some, but not more than 10%, of the glomerular capillaries
showed thrombosis; Score 2: 10 to 25%; Score 3: 26 to 50%; Score
4: 51 to 100%. Fifty glomeruli were evaluated from each rat and
the mean score for each group of rats was calculated.
Biochemical measurements
Urinary excretion rate of NO2 + NO3 was determined as
previously described [7]. Urinary excretion of cyclic 3', 5'-
guanosine monophosphate (cGMP) was determined by either
enzyme-linked immunoassay or radioimmunoassay (Amersham,
UK) [7, 14]. Both assays yielded similar results.
The following chemicals were used: N°-nitro-L-arginine methyl
ester (L-NAME; Sigma Chemicals, St. Louis, Missouri, USA);
lipopolysaccharide of E. col4 serotype 0127 (Difco, Detroit,
Michigan, USA); nitroglycerin (glyceryl trinitrate, GTN; Nitro-
stat, Parke-Davis, Morris Plains, New Jersey). Atrial natriuretic
peptide, human (ANP; Atriopeptin III, Sigma Chemicals); Brevi-
tal (Methohexital sodium, Eli Lilly Comp., Indianapolis, Indiana,
USA); hydralazine HCI (Sigma Chemicals).
Statistical analysis
Paired, two-tailed Student's t-test was used for comparison
between the baseline and experimental values. The blood pressure
recordings and intergroup comparisons were analyzed by analysis
of variance (ANOVA) and post-hoc Scheffe's test, with differ-
ences considered significant for P < 0.05. Values are presented as
mean standard error of the mean (sEM).
LPS
Fig. 1. Schematic representation of the
experimental design, including the timing of i.p.
injections (arrows) and intravenous infusions
(hatched bar).
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Fig. 2. Mean intraarterial blood pressure during the 7 hours of the experi-
ment in rats given LPS + L-NAME (•, N = 5), LPS + L-NAME + GTN(A, N = 4), LPS + L-NAME + ANP (, N = 5 at all time points, exceptN = 2 at 7 hr). Blood pressures were significantly lower in the LPS only
group compared to all other groups at 1, 3, 5 and 7 hr (P < 0.05). Data are
shown as mean SEM for each point.
Table 1. Urinary excretion of NO2 + NO3
Group
Experimental
protocol N
Urine flow
rated
mi/hr
UV NO2 + NO3
nmol/hr/100 g
body wt
Baseline
1
2
3
4
5
—
LPS + L-NAME
&GTN
&ANP
GTN only
LPS only
17
19
11
10
4
7
0.6 0.09
1.4 o.la
2.7 016ab
1.4 0.18
0.7 0.09
1.0 0.13a
75 6.4
49 8.2a
201 225ab
48 9.2a
248 251ab
321 36.5
P < 0.01 vs. baseline
bp < 0.01 vs. Group 1 and Group 3
cp < 0.01 vs. Group 2
d Urine was collected for 7 hr, except in Group 3 in which the collection
time averaged 5 hr.
Results
All rats that received LPS + L-NAME (Groups 1, 2 and 3)
appeared lethargic and ill at the end of the experimental period.
In Group 3 (LPS + L-NAME + ANP), all but 2 of the 12 rats
became moribund and had to be killed early, between 3 and 6-1/2
hours after the injection of LPS.
Mean arterial blood pressures for rats in Groups 1, 2, 3 and 5
are shown in Figure 2. Administration of LPS only was followed
by a slight decrease in blood pressure from 137 5.6 before
injection to 125 5.3 mm Hg at the end of the experiment. As
expected, the blood pressure increased in all rats receiving
L-NAME. The mean blood pressure values were not significantly
different between all the groups that received L-NAME, but were
significantly higher (P < 0.05) in these three groups compared to
the "LPS only" Group at time 1, 3, 5 and 7 hours.
Urinary flow rate increased compared to baseline in all five
experimental Groups 1,2, 3 and 5 (Table 1). The increase was most
marked for the LPS + L-NAME + GTN group, where it was more
than four times the baseline level. No diuretic effect of ANP was
noted in addition to that observed with LPS + L-NAME alone. Rats
given GTN only (Group 4) did not show an increase in urinary flow
Table 2. Urinary excretion of cGMP
Group
Experimental
protocol N
UV cGMP
nmol/hr/100 g
body wt
Baseline — 17 0.99 0.10
1 LPS + L-NAME 12 1.00 0.13
2 &GTN 8 1.13 0.27
3 &ANP 10 2.63 0.59
4 GTN only 4 0.89 0.043
5 LPS only 6 1.71 0.28a
rate. Urinary NO2 + NO3 excretion rates (UVNO2 + No3) are also
shown in Table 1. Injection of LPS resulted in a 4.3-fold increase in
the urinary excretion rate of these endproducts of NO metabolism,
compared to baseline. A similar increase in urinary excretion of NO2
+ NO3 required a dose of GTN of 10 1.gJkg/min (Group 4, GTh
only). L-NAME given with LPS (Group 1) completely inhibited the
increase in the urinary NO2 + NO3 excretion. In fact there was a
significant decrease in urinary excretion of the NO metabolites in
both the LPS + L-NAME and the LPS + L-NAME + ANP groups,
compared to baseline. GTN administration in LPS + L-NAME
treated rats induced a significantly higher urinary excretion of NO2 +
NO3 (P < 0.05 vs. LPS + L-NAME) which was similar to that
obtained in rats given GTN alone. Thus L-NAME did not block the
increase in NO2 + NO3 excretion resulting from GTN infusion.
Urinary cGMP excretion rates for the experimental groups are
shown in Table 2. LPS caused an increase in the urinary excretion
of cGMP (UVCGMP) of 1.7-fold compared to baseline. When
L-NAME was given with LPS (Group 1) no increase occurred.
GTN alone (Group 4) caused no increase in urinary cGMP
excretion. The infusion of GTN in LPS + L-NAME treated rats
also had no effect on cGMP excretion, while ANP infusion caused
a substantial increase (P < 0.05 vs. Groups 1 and 2).
While rats injected with LPS only showed very little evidence of
glomerular thrombosis, the animals that had been injected with
LPS + L-NAME demonstrated extensive thrombosis, often in-
volving the entire glomerular capillary bed (Fig. 3A). The extent
of thrombosis was similar in the subgroup of five rats who along
with LPS and L-NAME also received an intravenous infusion of
normal saline at a rate of 1.2 mi/hr (data not shown). For this
reason these rats were included in the analysis of the LPS +
L-NAME group. In the LPS + L-NAME + GTN group (Group
2), only scattered fibrin thrombin were seen in glomerular capil-
laries (Fig. 3B). The thrombosis score was 1.37 0.5 in this group,
compared to 3.02 0.4 (P < 0.025) for the LPS + L-NAME
group, and not significantly different than in the LPS only group
(0.59 0.4, P = 0.06). The administration of large doses of ANP
did not protect the kidneys from thrombosis. The thrombosis
score in rats treated with LPS + L-NAME + ANP was 2.68 0.5,
not significantly different from that obtained in the LPS +
L-NAME group (Fig. 4).
In separate studies we also tested another NO-independent
vasodilator, hydralazine. These rats developed glomerular throm-
bosis to a similar degree as rats treated with LPS + L-NAME or
with LPS + L-NAME + ANP (data not shown). Like the LPS +
E 180
E
160
140
120
100t
80
a)
—1 0 1 2 3 4
Time, hours
5 6 7
Urine was collected for 7 hr, except in Group 3, where most of the rats
died before the end of the experiment and the collection time was on the
average 5 hr.
a P < 0.05 vs. all others
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Fig. 3. (A). Representative photomicrograph of glomendi from a rat treated with LPS + L-NAME, as described in Methods and Figure 1. Extensive thrombi
are seen within most capillary loops (glomerular thrombosis score = 4). (Masson Trichrome stain, original magnification X 460). (B). Photomicrograph
of a glomerulus from a rat treated with LPS + L-NAME + GTN, as described in Methods and Figure 1. As shown, most glomeruli from the rats in
this group appeared normal with no evidence of thrombi (glomerular thrombosis score = 0. However, some glomeruli from this group had thrombi in
a minority of the glomerular capillaries (see Fig. 4). (Masson Trichrome stain, original magnification X 460).
0
Fig. 4. Glomendar thrombosis score in rats treated with LPS only (N = 15),
LPS + L-NAME (N = 19), LPS + L-NAME + GTN (N = 15), orLPS +
L-NAME + ANP (N = 12). The experimental design is given in Figure 1
and in the Methods. The glomerular thrombosis score is based on the
percentage of capillaries within a glomerulus which have thrombi. Data
shown represent mean SEM from at least fifty glomeruli from each
group. () denotes P < 0.05 versus both LPS + L-NAME and LPS +
L-NAME + ANP groups.
L-NAME + ANP, rats receiving LPS + L-NAME + hydralazine
also showed reduced survival time in this protocol.
Discussion
We have previously demonstrated that increased production of
NO during endotoxemia was crucial in protecting against glomer-
ular capillary thrombosis [7]. Rats given LPS increased their
urinary excretion of NO2 + NO3 and did not show substantial
fibrin deposition in the glomeruli. When the NO formation was
inhibited with L-NAME, extensive glomerular thrombosis devel-
oped. L-NAME alone did not cause fibrin deposition [7]. In the
current study, we have demonstrated that when endogenous NO
synthesis is inhibited, exogenous nitric oxide can protect the
glomeruli from endotoxin-induced thrombosis. As an exogenous
NO donor we chose GTN [17, 18], in a dose that gave a threefold
increase in the urinary excretion of NO2 + NO3, to mimic the
urinary excretion of NO metabolites seen in LPS-treated rats
(Table 1). In contrast ANP, a cGMP dependent but NO-indepen-
dent vasodilator, caused no increase in the excretion of NO
metabolites, and glomerular thrombosis was not prevented. More-
over, hydralazine, another powerful vasodilator with a different
mechanism of action from either GTN or ANP, also failed to
arrest glomerular thrombosis.
Since L-NAME in the dose used in this study acts as a
vasoconstrictor [7, 19], we thought it important to consider the
possibility that L-NAME induced vasoconstriction and ischemia
may contribute to the glomerular thrombosis seen in LPS-treated
rats. Our findings argue against this contention for several rea-
sons: (1) L-NAME alone does not cause glomerular thrombosis
[7]; (2) although organic nitrates are vasodilators, infusion of
GTN in amounts similar to those used in the current study was
found not to affect renal vascular resistance in rats [20]; (3) ANP
has been shown to ameliorate the development of acute renal
failure caused by vasoconstriction and ischemia [14, 15]. However,
we found that ANP administered in doses large enough to cause
a substantial increase in urinary cGMP levels failed to prevent
heavy fibrin deposition in the glomeruli; and (4) another unre-
lated vasodilator, hydralazine, also failed to prevent the glomer-
ular thrombosis observed with LPS + L-NAME. Thus, we con-
clude that renal vasoconstriction, leading to a decrease in renal
blood flow, does not account for the thrombosis observed in these
rats.
Although there are many studies showing that GTN generates
NO in vitro [21—23], our study seems to be the first to show that the
administration of an organic nitrate in vivo is followed by an
increase in urinary excretion of NO metabolites. To our initial
surprise, no increase in urinary cGMP occurred during GTN
infusion, either when GTN was infused alone or together with
LPS + L-NAME. Previous studies in our laboratory have shown
an increase in urinary cGMP excretion in rats where NO synthesis
was stimulated with acetylcholine [19] or LPS [7]. It is well
established that organic nitrates, such as GTN, vasodilate through
the activation of soluble guanylate cyclase resulting in an increase
in intracellular cGMP [24, 25]. However, infusion of GTN was
found not to increase the urinary excretion of cGMP in patients
[26]. Furthermore, in patients with congestive heart failure,
nitroglycerin ointment in doses sufficient to have a clear hemody-
namic effect did not cause a measurable increase in plasma cGMP
[27]. Thus, it appears that in vivo administration of organic
nitrates does not result in increases in urinary cGMP, despite
increases in NO metabolites in the urine. The reason for this
disparity is not known.
This is the first study that shows that an organic nitrate can
prevent the formation of glomerular thrombosis. However, an
antithrombotic effect of nitrates has previously been suggested
[28]. Platelet deposition on damaged endothelium in the carotid
artery of pigs can be inhibited by organic nitrates [29]. Similarly,
platelet aggregates in the retina of humans can be disaggregated
using GTN [30]. Furthermore, patients treated with intravenous
GTN have prolonged bleeding times and decreased platelet
adhesion to endothelial cells [28, 31]. ANP, on the other hand, has
not been found to affect platelets, presumably because ANP acts
only on particulate guanylate cyclase, which is not present in
platelets [32]. To further elucidate the action of GTN on platelets,
we attempted to measure the cGMP content of platelets from the
rats in our study [6, 33]. We found that in rats given LPS +
L-NAME, the platelets had aggregated and could not be effec-
tively separated from the erythrocytes. In rats given LPS +
L-NAME + GTN, the platelets were not aggregated, but the lack
of comparison groups made it impossible to assess the effect of
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GTN on platelet cGMP. However, the observation that platelets
from LPS + L-NAME rats are highly aggregatory is consistent
with the concept that platelet aggregation may contribute to the
glomerular thrombosis we observe in these animals. Furthermore,
the apparent correction of this enhanced aggregation in the LPS
+ L-NAME + GTN group, supports our hypothesis that exoge-
nous NO protects against glomerular thrombosis by decreasing
platelet aggregation.
Based on our studies, we conclude that either nitric oxide, or a
substance akin to it, is released from GTN in quantities sufficient
to increase NO levels in vivo, as evidenced by the increased
urinary NO2 + NO3 excretion. Furthermore, the NO produced
from GTN prevents glomerular thrombosis in rats given LPS and
inhibitors of endogenous NOS. We speculate that the prevention
of glomerular capillary thrombosis by GTN is primarily due to the
effect of NO on platelet function. If the use of inhibitors of NOS
for the treatment of septic shock becomes clinically feasible,
simultaneous treatment with nitroglycerin or similar exogenous
NO donors may prevent intravascular coagulation and organ
thrombosis.
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